PAQ is not cleared for use in the United States

Introduction to PAQ®

PAQ is a wearable insulin delivery device that delivers up to 3 days of continuous pre-set basal insulin plus on- demand mealtime bolus in 2 unit increments.

PAQ has two components:

Insulin Reservoir

  • Delivers 3 days of steady basal insulin
  • Provides injection-free bolus with a push of the button


  • Notifies wearer when to replace the insulin reservoir

How to Use PAQ®

PAQ® Facts

  • Developed specifically for people with type 2 diabetes
  • Up to 3 days of continuous subcutaneous insulin delivery
  • No programming or infusion sets
  • Worn on the abdomen
    • Small, ergonomic design
    • Be active, sleep, eat, exercise
    • Bathe, shower, swim (depth up to 6 ft)
  • Utilizes U100 rapid-acting insulin

  • 7 preset basal doses
  • 2 bolus units delivered with each button push
  • Delivers up to 330 units over 3 days

PAQ® Clinical Results

A recently completed clinical study evaluated the ability of people with Type 2 diabetes to use simple insulin infusion with the PAQ insulin delivery device to replace multiple daily injections. Study endpoints included glycemic control, patient satisfaction and safety. The only change from the baseline period of multiple daily injections and PAQ treatment was using the device to deliver insulin. Click here to view the study design.

PAQ is Simple to Train, Use and Transition1,2
  • With only one hour of training all participants were able to easily assemble and use PAQ without user errors.
  • All study participants were "very satisfied" (83%) or "satisfied" (17%) with the time it took to learn how to use PAQ and to administer bolus doses with PAQ
  • Transition was done simply and safely with 75% of the trial participants transitioning to PAQ with the first basal rate selected.
PAQ Effectively and Safely Delivers Basal and Bolus Insulin2
  • Changes in self-monitored blood glucose values during PAQ therapy showed a trend toward improved glycemic control compared to baseline at multiple points throughout the day
  • Blinded continuous glucose monitoring (CGM) data during PAQ therapy also revealed a trend toward improved glycemic control
  • Total daily insulin dose (TDD) was similar on PAQ to baseline MDI therapy
    • Half the participants were able to reduce their insulin usage by more than 10% while on PAQ
  • PAQ was well tolerated
  • Hypoglycemia throughout the study was comparable to MDI, with fewer participants having hypoglycemia during the PAQ treatment period
  • Additional data being released at the ADA 73rd Scientific Sessions being held in Chicago.
PAQ Delivers Freedom From Daily Injections1,3
  • Overall barriers to insulin therapy were reduced significantly with use of PAQ
    • According to a validated questionnaire, Barriers to Insulin Treatment (BIT), there was a strong and clinically significant effect of PAQ in the mean BIT total score.
    • Patients perceived less hardship from insulin therapy, less stigmatization by insulin injection and less fear of hypoglycemia.
  • Study participants found the device to be less embarrassing, less of a burden and less painful than current insulin injection treatments.


A Study to Assess the Performance of PAQ®, a Simple 3-Day Basal Bolus Insulin Delivery Device, after 12 weeks of treatment in People with Type 2 Diabetes

J.K. Mader1, L.C. Lilly2, F. Aberer1, T. Po╠łttler1, M. Trautmann1, T.R. Pieber1,3 1062-P. Poster session presented at: ADA 75th Scientific Sessions; 2015 Jun 5-9; Boston, MA

A Feasibility Assessment of PAQ®, a Simple 3-Day Basal/Bolus Insulin Delivery Device, in Patients with Type 2 Diabetes

J.K. Mader, L.C. Lilly, F. Aberer, J. Pachatz, S. Korsatko, E. Strock, R. Mazze, P. Damsbo, T.R. Pieber, 990-P. Poster session presented at: ADA 73rd Scientific Sessions; 2013 Jun 21-25; Chicago, IL

Use of PAQ®, a Simple 3-Day Basal/Bolus Insulin Delivery Device, Reduces Barriers to Insulin Therapy in Patients with Type 2 Diabetes

N. Hermanns, L.C. Lilly, J.K. Mader, F. Aberer, J. Paschatz, S. Korsatko, J. Warner, T.R. Pieber, 812-P. Poster session presented at: ADA 73rd Scientific Sessions; 2013 Jun 21-25; Chicago, IL